THT Conference

Attendees, exhibitors & solutions

Who this event is for

Industry trends

Key trends shaping this market and its wider industry.

Arrival airports

Choose from the following airports, with convenient access to the event and venue.

Hotel tiers

A range of accommodation options near the venue and across key areas.

Local transport

Get around the city with these convenient transport options.

Frequently asked

Glossary

1

Heart failure (HF)

A clinical syndrome in which the heart cannot pump or fill adequately for the body's needs. THT's programme spans the full phenotype range, from reduced to preserved ejection fraction, and the device, drug and monitoring technologies used to manage each.

2

HFrEF

Heart failure with reduced ejection fraction, conventionally an LVEF of 40% or below. Most durable device and mechanical circulatory support evidence discussed at THT is generated in this phenotype.

3

HFpEF

Heart failure with preserved ejection fraction, where filling pressures are elevated despite a normal pump fraction. A fast-growing share of the heart failure population and a frequent topic for diagnostic and remote monitoring technology.

4

LVEF (left ventricular ejection fraction)

The percentage of blood ejected from the left ventricle per beat. It is the main stratification variable for trial eligibility, device indications and reimbursement discussions on the show floor.

5

NYHA functional class

A I-IV symptom scale describing how much ordinary activity is limited by breathlessness or fatigue. Commonly quoted as an inclusion criterion in heart failure trials presented at the conference.

6

GDMT (guideline-directed medical therapy)

The four-pillar drug foundation for HFrEF: renin-angiotensin system inhibition (ARNI/ACE inhibitor/ARB), evidence-based beta-blocker, mineralocorticoid receptor antagonist and SGLT2 inhibitor. Device and monitoring companies position their products as add-ons to optimised GDMT.

7

NT-proBNP / BNP

Natriuretic peptide biomarkers released when ventricular wall stress rises; used to diagnose, risk-stratify and monitor heart failure. Frequently cited as a screening and endpoint measure in trial data.

8

PA pressure monitoring

Implantable pulmonary artery pressure sensor systems (CardioMEMS-type) that transmit daily haemodynamic readings so clinicians can titrate diuretics before symptoms escalate; one of the longest-running device categories in the THT exhibitor mix.

9

Remote patient monitoring (RPM)

Home capture of weight, blood pressure, symptoms or device diagnostics between clinic visits. Reimbursement pathways and alert fatigue are recurring practical questions at the conference.

10

LVAD (left ventricular assist device)

A surgically implanted pump that supports the failing left ventricle in advanced heart failure, available as destination therapy or bridge to transplant. Durable LVAD design, driveline infection and patient selection dominate the mechanical support track.

11

Mechanical circulatory support (MCS)

The umbrella for temporary percutaneous pumps, extracorporeal circuits and durable assist devices used in cardiogenic shock and advanced heart failure; a core technology family for THT exhibitors.

12

Cardiac transplantation

The reference therapy for end-stage heart failure. Sessions focus on candidate selection, waiting-list management and how device support bridges patients toward transplant.

13

Cardiac contractility modulation (CCM)

A device therapy that delivers non-excitatory electrical signals during the absolute refractory period to improve contractility in selected HFrEF patients; a niche but recurring technology on the exhibit floor.

14

Digital endpoints

Trial measures collected by wearables, apps or implanted devices (activity, sleep, haemodynamics) rather than site visits. A practical topic for sponsors planning heart failure studies and for decentralised trial vendors.

15

Readmission and the virtual ward

Post-discharge models that combine remote data, nurse-led triage and rapid clinic review to keep heart failure patients out of hospital; a common commercial case for monitoring platforms.

16

Coverage and reimbursement pathway

The US route from FDA clearance to CMS or commercial payer coverage. For device start-ups at THT this is usually the difference between a pilot site and a national launch, so coding and coverage sessions draw clinical, industry and payer attendees alike.